Centrifugation Liver Support Using Regional Mesylate Anticoagulation is Safe for Liver Failure Patients with High Risk of Bleeding
Patients with acute liver failure (ALF) or acute-on-chronic liver failure (ACLF) are at high risk of bleeding with traditional artificial liver support systems. To address the bleeding risk in liver failure patients, the safety of regional mesylate anticoagulation (RMA) in centrifugation artificial liver support systems (cALSS) is proposed for study.
Authors
- Fei Sun (ORCID: https://orcid.org/0000-0001-6109-9137)
- Xinfang Zhu
- Jianming Zheng (ORCID: https://orcid.org/0000-0003-1471-9078)
- Quanbao Zhang
- Qi Zhang (ORCID: https://orcid.org/0000-0003-3813-8032)
- Bo Wang (ORCID: https://orcid.org/0000-0001-9755-498X)
- Rong Xia (ORCID: https://orcid.org/0000-0002-2463-6340)
- Ruidong Li (ORCID: https://orcid.org/0000-0002-0199-9069)
- Hong-Yuan Xue
Publication Details
- Journal
- Journal of Clinical and Translational Pathology
- Published
- 2025-03-17
- DOI
- https://doi.org/10.14218/jctp.2024.00036
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China